Janssen Pharmaceutica Nv

Tibotec Pharmaceuticals Ltd.

Janssen Sciences Ireland Unlimited Company

Janssen R&d Ireland

Alfred Elisabeth Stappers

Jérôme Emile Georges Guillemont

Alex Herman Copmans

Jozef Peeters

Roger Petrus Gerebern Vandecruys

Paul Stoffels

Paul Theodoor Agnes Stevens

Christopher A Teleha

Yolande Lydia Lang

Didier Philippe Robert Schils

Koen Johan Herman Weerts

Shane Barry Robinson

Paul Theodoor Stevens

Roger Petrus Vandecruys

Kenneth Jerome Wilson

Jean-Pierre André Marc Bongartz

Krzysztof Kolodziejczyk

Didier Philippe Schils

The present invention relates to an improved process for preparing [(1S,2R)-3-[[(4-aminophenyl)-sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester&#x2014;which compound is also known under its INN as darunavir&#x2014;by reacting carbonic acid 2,5-dioxo-1-pyrrolidinyl [(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]ester with 4-amino-N-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)-benzenesulfonamide in ethanol as solvent. Furthermore said process allows for darunavir to be isolated immediately in its ethanolate form, i.e. darunavir monoethanolate, which is the marketed form of darunavir under the tradename Prezista&#x2122;.

Simplified procedure for the preparation of darunavir

The present invention relates to an improved process for preparing [(1S,2R)-3-[[(4-aminophenyl)-sulfonyl](2-methyl-propyl)amino]-2-hydroxy-1-(phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester&#x2014;which compound is also known under its INN as darunavir&#x2014;by reacting carbonic acid 2,5-dioxo-1-pyrrolidinyl[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl]ester with 4-amino-N-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)-benzenesulfonamide in ethanol as solvent. Furthermore said process allows for darunavir to be isolated immediately in its ethanolate form, i.e. darunavir monoethanolate, which is the marketed form of darunavir under the tradename Prezista&#x2122;.

The present invention is directed to a process for the preparation of heterocyclic ester derivatives of formula I wherein A, SEM, and Ware as defined herein. Such compounds are useful as intermediates in the synthesis of derivatives useful as protein tyrosine kinase inhibitors, more particularly inhibitors of c-fms kinase.

Process for the preparation of heterocyclic ester derivatives

The present invention is directed to a process for the preparation of heterocyclic derivatives of formula I wherein J, X, Z, and Rare as defined herein. Such compounds are useful as protein tyrosine kinase inhibitors, more particularly inhibitors of c-fms kinase.

Process for the preparation of C-FMS kinase inhibitors

This invention relates to a process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)-amino]benzonitrile (I) starting from a 4-oxo-1,6-dihydro-pyrimidinylcarboxylic acid ester (II) or starting from a guanidine derivative which is reacted with an alkoxy-methylene malonic acid ester to an ester (II) which is converted to (I), which reaction sequence may be a one-pot procedure.

Process for preparing 4-[(1,6-dihydro-6-OXO-2-pyrimidinyl)amino]benzonitrile

Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile

The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.

Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile

Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile

Growing community of inventors

Oud-Turnhout, Belgium

Alfred Elisabeth Stappers